Tekla Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Tekla Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$20.5M	Sell	179,437 -106,216	-37%	-$13.7M	0.8%	35
2023 Q1	$39.4M	Buy	285,653 +144,694	+103%	+$18.8M	1.5%	21
2022 Q4	$18.3M	Sell	140,959 -25,000	-15%	-$2.9M	0.69%	38
2022 Q3	$18.3M	Sell	165,959 -46,206	-22%	-$4.66M	0.75%	37
2022 Q2	$15.9M	Sell	212,165 -15,532	-7%	-$1.14M	0.63%	42
2022 Q1	$17.8M	Sell	227,697 -88,200	-28%	-$6.75M	0.62%	43
2021 Q4	$28.4M	Sell	315,897 -110,617	-26%	-$9.46M	0.92%	34
2021 Q3	$39.4M	Buy	426,514 +233,290	+121%	+$18M	1.27%	23
2021 Q2	$15M	Buy	193,224 +64,237	+50%	+$4.87M	0.49%	52
2021 Q1	$9.61M	Sell	128,987 -77,500	-38%	-$7.15M	0.33%	77
2020 Q4	$35.2M	Hold	206,487	–	–	1.24%	20
2020 Q3	$29M	Buy	206,487 +66,358	+47%	+$10.1M	1.09%	22
2020 Q2	$22.5M	Hold	140,129	–	–	0.86%	28
2020 Q1	$13.7M	Sell	140,129 -41,494	-23%	-$4.74M	0.62%	38
2019 Q4	$23.4M	Buy	181,623 +41,344	+29%	+$4.17M	0.89%	28
2019 Q3	$10.6M	Sell	140,279 -7,568	-5%	-$894K	0.46%	54
2019 Q2	$22.5M	Hold	147,847	–	–	0.92%	28
2019 Q1	$17.6M	Sell	147,847 -43,990	-23%	-$5.66M	0.72%	35
2018 Q4	$20.9M	Sell	191,837 -31,345	-14%	-$3.92M	0.9%	28
2018 Q3	$36M	Sell	223,182 -11,307	-5%	-$1.55M	1.31%	19
2018 Q2	$31M	Sell	234,489 -144,027	-38%	-$13.6M	1.18%	23
2018 Q1	$28M	Buy	378,516 +44,116	+13%	+$2.94M	1.09%	25
2017 Q4	$18.6M	Sell	334,400 -202,200	-38%	-$10.7M	0.72%	34
2017 Q3	$24.3M	Buy	536,600 +25,000	+5%	+$999K	0.87%	28
2017 Q2	$17.2M	Hold	511,600	–	–	0.64%	35
2017 Q1	$15.1M	Buy	511,600 +45,300	+10%	+$1.4M	0.59%	35
2016 Q4	$12.8M	Buy	466,300 +252,200	+118%	+$10.1M	0.54%	41
2016 Q3	$13.1M	Buy	+214,100	New	+$6.47M	0.51%	47
2015 Q2	–	Sell	-230,300	Closed	-$3.06M	–	132
2015 Q1	$3.06M	Sell	230,300 -115,100	-33%	-$1.53M	0.12%	94
2014 Q4	$5M	Hold	345,400	–	–	0.23%	73
2014 Q3	$7.29M	Buy	+345,400	New	+$7.8M	0.34%	64

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tekla Capital Management's SRPT Position: Q2 2023 in Review

Tekla Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 37% in Q2 2023, selling an estimated $13.7M and leaving 179,437 shares worth $20.5M. The position accounts for 0.8% of the portfolio, ranked #35.

Tekla Capital Management first reported a position in SRPT in Q3 2014 and has held it in 31 quarters since. The position peaked at $39.4M in Q3 2021. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Tekla Capital Management held 179,437 shares of Sarepta Therapeutics worth $20.5M as of Q2 2023.
Tekla Capital Management sold 106,216 Sarepta Therapeutics shares in Q2 2023, an estimated $13.7M.
Sarepta Therapeutics made up 0.8% of Tekla Capital Management's portfolio in Q2 2023, its #35 holding.
Tekla Capital Management first reported a position in Sarepta Therapeutics in Q3 2014 and has held it in 31 quarters since.
Tekla Capital Management's Sarepta Therapeutics position peaked at $39.4M in Q3 2021.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.